CAH
CVS
MCK
Same old supply chain, now with a longer lease
Cardinal Health and McKesson basically walked into CVS's office and said, “Let’s keep this thing going.” Both distributors signed extensions that keep their pharmaceutical distribution relationships alive through June 30, 2032, which is a long time in healthcare and an even longer time in corporate procurement.
For Cardinal, the deal matters because it preserves the current scope of distribution services with one of the biggest names in drug retail. Translation: less churn, more visibility, and one fewer thing for investors to worry about while the healthcare supply chain keeps doing its extremely unglamorous but very profitable thing.
The real investor hook
Cardinal also reaffirmed its FY2027 adjusted earnings growth guidance of 13% to 15%, or $12.40 to $12.60 per share, above consensus at $12.04. It left its longer-term 12% to 14% adjusted EPS growth target intact too. That combo is basically management saying: the CVS relationship is stable, the growth plan is still on track, and no, we’re not improvising here.
McKesson echoed the same vibe, reaffirming its FY2027 adjusted EPS outlook of $44.20 to $45 and a long-term growth rate of 13% to 16%. So while the headline reads like a boring contract renewal, the market got something more interesting: two major distributors signaling that their CVS pipeline is secure and their earnings scripts haven’t changed.
Big picture
This is the kind of news that doesn’t sound sexy until you remember how much Wall Street loves predictability. In a sector where stability can be worth more than fireworks, locking in a major customer through 2032 is basically the financial equivalent of finding out your rent won’t jump for six years.